Publication: Role of biomarkers for the diagnosis of prion diseases: a narrative review
| dc.contributor.author | Altuna Azkargorta, Miren | |
| dc.contributor.author | Ruiz, Íñigo | |
| dc.contributor.author | Zelaya Huerta, María Victoria | |
| dc.contributor.author | Mendióroz Iriarte, Maite | |
| dc.contributor.department | Ciencias de la Salud | es_ES |
| dc.contributor.department | Osasun Zientziak | eu |
| dc.date.accessioned | 2022-07-19T07:33:41Z | |
| dc.date.available | 2022-07-19T07:33:41Z | |
| dc.date.issued | 2022 | |
| dc.date.updated | 2022-06-30T11:50:40Z | |
| dc.description.abstract | Prion diseases are progressive and irreversible neurodegenerative disorders with a low incidence (1.5–2 cases per million per year). Genetic (10–15%), acquired (anecdotal) and sporadic (85%) forms of the disease have been described. The clinical spectrum of prion diseases is very varied, although the most common symptoms are rapidly progressive dementia, cerebellar ataxia and myoclonus. Mean life expectancy from the onset of symptoms is 6 months. There are currently diagnostic criteria based on clinical phenotype, as well as neuroimaging biomarkers (magnetic resonance imaging), neurophysiological tests (electroencephalogram and polysomnogram), and cerebrospinal fluid biomarkers (14-3-3 protein and real-time quaking-induced conversion (RT-QuIC)). The sensitivity and specificity of some of these tests (electroencephalogram and 14-3-3 protein) is under debate and the applicability of other tests, such as RT-QuIC, is not universal. However, the usefulness of these biomarkers beyond the most frequent prion disease, sporadic Creutzfeldt–Jakob disease, remains unclear. Therefore, research is being carried out on new, more efficient cerebrospinal fluid biomarkers (total tau, ratio total tau/phosphorylated tau and neurofilament light chain) and potential blood biomarkers (neurofilament light chain, among others) to try to universalize access to early diagnosis in the case of prion diseases. | en |
| dc.description.sponsorship | MA acknowledges support from a Río Hortega Fellowship (CM19/00066) by the Carlos III Health Institute. | en |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.citation | Altuna, M.; Ruiz, I.; Zelaya-Huerta, M. V.; Mendioroz, M. (2022). Role of biomarkers for the diagnosis of prion diseases: a narrative review. Medicina-Lithuania. 58,4 | en |
| dc.identifier.doi | 10.3390/medicina58040473 | |
| dc.identifier.issn | 1010-660X | |
| dc.identifier.uri | https://academica-e.unavarra.es/handle/2454/43331 | |
| dc.language.iso | eng | en |
| dc.publisher | MDPI | en |
| dc.relation.ispartof | Medicina-lithuania, 2022, 58 (4),473 | en |
| dc.relation.publisherversion | https://doi.org/10.3390/medicina58040473 | |
| dc.rights | © 2022 by the authors. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited | en |
| dc.rights.accessRights | Acceso abierto / Sarbide irekia | es |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | en |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Biomarkers | en |
| dc.subject | Dementia | en |
| dc.subject | Diagnosis | en |
| dc.subject | Neurodegeneration | en |
| dc.subject | Prion disease | en |
| dc.title | Role of biomarkers for the diagnosis of prion diseases: a narrative review | en |
| dc.type | Artículo / Artikulua | es |
| dc.type | info:eu-repo/semantics/article | en |
| dc.type.version | Versión publicada / Argitaratu den bertsioa | es |
| dc.type.version | info:eu-repo/semantics/publishedVersion | en |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | fc740a9f-a1f1-46c3-bc2d-664eccdb4feb | |
| relation.isAuthorOfPublication.latestForDiscovery | fc740a9f-a1f1-46c3-bc2d-664eccdb4feb |